Hyderabad-based Dr Reddy's Laboratories sprung a surprise on Wednesday when it announced that it will acquire the domestic business of Wockhardt Pharma for Rs 1,850 crore. The deal signifies Dr Reddy's de-risking strategy with regards to its US business, which has taken a hit because of regulatory actions. GV Prasad, CEO of Dr Reddy's, said the future capital allocation by the company will come into emerging markets such as India. Edited excerpts:from Expert Views-Markets-Economic Times
Read The Rest:economictimes...
